A retrospective analysis for early-stage non-endometrioid endometrial cancers
Radiation Oncology Journal · 30.06.2026 · 44 (2) · 90-96
DOI: 10.3857/roj.2025.00724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Radiation Oncology Journal, erschienen am 30.06.2026. Verfasst von Eunkyoung Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
This study aimed to investigate treatment outcomes and explore optimal adjuvant treatment options for patients with early-stage uterine serous carcinoma (USC) and clear cell carcinoma (CCC).Materials and Methods: We retrospectively reviewed the records of 63 patients diagnosed with stage I–II (2009 International Federation of Gynecology and Obstetrics [FIGO]) USC or CCC. Survival outcomes were estimated using the Kaplan-Meier method, and comparisons between groups were performed with the log-rank test.
Results
Among the 63 patients, 36 (57.1%) had USC and 25 (39.7%) had CCC. According to the revised 2023 FIGO staging system, 23 patients (36.5%) were stage IC, and 40 (63.5%) were stage IIC. Adjuvant treatment included no adjuvant therapy (23.8%), chemotherapy alone (39.7%), radiotherapy alone (28.6%), and combined chemotherapy plus radiotherapy (8.0%). After a median follow-up of 54 months (range, 5 to 227 months), the 5-year progression-free survival (PFS) and overall survival (OS) for the entire cohort were 89.5% and 85.7%, respectively. Patients with CCC had a 5-year PFS of 95.8% and OS of 92.3%, whereas those with USC had a 5-year PFS of 85.1% and OS of 81.4%. Most recurrences (7/63, 11.1%) were distant, occurring predominantly in USC cases (6/7) and 2023 stage IIC (7/7).
Conclusion
In this retrospective study, early-stage USC and CCC had very favorable PFS and survival outcomes. Thus, future randomized clinical trial or large cohort study is necessary to determine the optimal adjuvant treatments in these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Lee, E., Cho, W. K., Park, W., Lee, J. W., Lee, Y. Y., Choi, C. H., & Kim, T. J. (2026). A retrospective analysis for early-stage non-endometrioid endometrial cancers. Radiation Oncology Journal, 44(2), 90-96. https://doi.org/10.3857/roj.2025.00724
Vancouver
Lee E, Cho WK, Park W, Lee JW, Lee YY, Choi CH, et al. A retrospective analysis for early-stage non-endometrioid endometrial cancers. Radiation Oncology Journal. 2026;44(2):90-96. doi:10.3857/roj.2025.00724
BibTeX
@article{Lee2026,
author = {Lee, Eunkyoung and Cho, Won Kyung and Park, Won and Lee, Jeong-Won and Lee, Yoo-Young and Choi, Chel Hun and Kim, Tae-Joong},
title = {A retrospective analysis for early-stage non-endometrioid endometrial cancers},
journal = {Radiation Oncology Journal},
year = {2026},
volume = {44},
number = {2},
pages = {90--96},
doi = {10.3857/roj.2025.00724}
}
EUVIMED